In general, the use of ruxolitinib has been authorized in COVID-19 patients with respiratory insufficiency, and clinical evidence has suggested that this inhibitor of JAK1 and JAK2 can reduce inflammatory pulmonary reaction and potentially prevent the use of intensive care. Here, JAK2 is linked to COVID-19.